Ignite Creation Date:
2024-05-06 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 2:28 PM
Study NCT ID:
NCT05306041
Status:
RECRUITING
Last Update Posted:
2024-02-22
First Post:
2022-03-09
Brief Title:
Neoadjuvant Endocrine Therapy - the PI3K Inhibitor Inavolisib in HER2 HR PIK3CA Mutant Early Breast Cancer
Sponsor:
German Breast Group
Organization:
German Breast Group